Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder SyndromeChristopher R. Chapple, Steve Deacon, T. Kuwayama et al.|The Journal of Urology|2013Cited by 35
777 SAFETY, TOLERABILITYAND PHARMACOKINETIC OF MULTIPLE ASCENDING DOSES OF THE EP-1 RECEPTOR ANTAGONIST ONO-8539, A POTENTIAL NEW AND NOVEL THERAPY TO OVERACTIVE BLADDER IN HEALTHY YOUNG AND ELDERLY SUBJECTSDarren Wilbraham, Séverine Vincent, Takahiro Masuda et al.|European Urology Supplements|2010Cited by 5
783 URINARY PROSTAGLANDIN E2 LEVELS ARE ELEVATED IN PATIENTS WITH OVERACTIVE BLADDER AND PAINFUL BLADDER SYNDROME AND CORRELATE WITH BLADDER DIARY SYMPTOMSPaul Abrams, Steve Deacon, Séverine Vincent et al.|European Urology Supplements|2010Cited by 1